Ultime notizie per Steris (NYSE:STE) Azioni

Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Steris PLC

Stream Media Corp

Santech Holdings Limited - American Depositary Shares

Santech Holdings Ltd

Scatec ASA

STEER Technologies Inc Ordinary Shares

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

Majestic Dragon AeroTech Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Step Finance - United States Dollar

STERLING CHECK CORP COM

Lido stETH

ST Energy Transition I Ltd Warrants (02/12/2026)

ST Energy Transition I Ltd

Stevia Corp

SRH Total Return Fund, Inc.

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Steris to report an earnings per share (EPS) of $2.12.
Steris bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 2.36% drop in the share price the following trading session.
Here's a look at Steris's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.98</td>
<td>2.38</td>
<td>2.17</td>
<td>2.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.03</td>
<td>2.58</td>
<td>2.22</td>
<td>2.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730836886_0.png" alt="eps graph" />
<h3>Performance of Steris Shares</h3>
Shares of Steris were trading at $225.82 as of November 04. Over the last 52-week period, shares are up 10.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/STE/earnings">To track all earnings releases for Steris visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Outlook For Steris

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>KGI Securities analyst Terry Lee upgraded Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Neutral to Outperform and announced a $276 price target. Tesla shares closed at $213.65 on Wednesday. <a href="https://www.benzinga.com/quote/tsla/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Matt O&#8217;Connor upgraded the rating for Regions Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) from Hold to Buy and increased the price target from $24 to $26. Regions Finl shares closed at $23.64 on Wednesday. <a href="https://www.benzinga.com/quote/RF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730076/mark-strouse">JP Morgan analyst Mark Strouse</a> upgraded NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Underweight to Neutral but lowered the price target from $25 to $22. NextEra Energy Partners shares closed at $21.01 on Wednesday. <a href="https://www.benzinga.com/quote/NEP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e8b4df71e7bd60001d9d077/jason-bednar">Piper Sandler analyst Jason Bednar</a> upgraded STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and boosted the price target from $230 to $260. Steris shares closed at $221.15 on Wednesday. <a href="https://www.benzinga.com/quote/STE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Bascome Majors upgraded the rating for Canadian Pacific Kansas City Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) from Neutral to Positive but slashed the price target from $94 to $92. Canadian Pacific Kansas shares closed at $78.83 on Wednesday. <a href="https://www.benzinga.com/quote/CP/analyst-ratings">See how other analysts view this stock.</a> </li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png" alt="" class="wp-image-612833" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243.png 1228w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41517173/eaton-transdigm-and-a-big-bank-on-cnbcs-final-trades">Eaton, TransDigm And A Big Bank On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>

Upgrades

Markets

Analyst Ratings

Trading Ideas

TSLA

This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

WIIM

STERIS shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $230 to $260.

4 analysts have expressed a variety of opinions on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $262.5, with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is apparent, with the current average reflecting a 3.96% increase from the previous average price target of $252.50.
<img src="https://www.benzinga.com/files/images/story/2024/1729778431_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Steris's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Steris's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Breaking Down Steris's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Steris's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.12%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Steris

Piper Sandler analyst Jason Bednar upgrades Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and raises the price target from $230 to $260.

News

Price Target

Piper Sandler Upgrades Steris to Overweight, Raises Price Target to $260

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Tuesday.</a>
Constellation Brands has revised its FY25 comparable EPS forecast to $13.60 &#8211; $13.80, compared to the previous forecast of $13.50 &#8211; $13.80. This is compared to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the $13.70 estimate.</a>
Constellation Brands projects FY25 reported EPS in the range of $3.05 &#8211; $7.92, down from the previous forecast of $14.63 &#8211; $14.93 and well below the $14.62 estimate.
The company anticipates a hefty non-cash goodwill impairment loss of around $1.5 billion to $2.5 billion for its Wine and Spirits division in the second quarter of fiscal 2025, which is factored into the revised reported&nbsp;EPS outlook.
The company also revised its Enterprise net sales growth forecast to 4% &#8211; 6% (from 6% &#8211; 7% prior), citing incremental macroeconomic headwinds affecting consumers, particularly unemployment and prolonged inventory destocking in wine and spirits markets.
The company updated Beer net sales growth to 6% &#8211; 8%&nbsp;(from 7% &#8211; 9% prior) and Wine and Spirits net sales outlook to (6)% &#8211; (4)% (from (0.5)% &#8211; 0.5% prior).
&#8220;While ongoing macroeconomic headwinds, particularly rising unemployment, have led to a recent deceleration in the rate of growth of consumer demand for our products, we are on track to deliver a solid mid single-digit volume increase this fiscal year for our Beer Business,&#8221; said Constellation Brands President and Chief Executive Officer Bill&nbsp;Newlands.
&#8220;These trends have been most notable in the top five states for our Beer Business, which account for just over half of our volumes; however, we continue to see volume growth within the low to mid single-digit range in these states and within the high single-digit range on average across the rest of the country.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/23/05/32347463/steris-delivered-strong-q4-performance-but-analyst-call-fy24-outlook-mixed" rel="noreferrer noopener">Steris Delivered Strong Q4 Performance, But Analyst Call FY24 Outlook Mixed</a>
The CEO noted that improvements from earlier initiatives benefit major brands in the Wine and Spirits sector, although category challenges continue to impact the fiscal year outlook.
Despite these challenges, the company has outpaced the CPG sector growth by nearly 3 percentage points in dollar sales and its Beer Business has achieved notable gains, including being the top dollar share gainer in its category and the third largest in the Beverage industry.
RBC Capital analyst Nik Modi reaffirms Constellation Brands with an Outperform rating and maintains a $308 price target.
Price Action: STZ shares are sharing higher by 3.08% to $248.12 at last check Tuesday.
Photo: Engin Akyurt from Pixabay.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i" target="_blank" rel="noreferrer noopener">Tesla's China Rivals Report Steady August Sales Performance Amid Intense Price Competition: What Investors Should Know</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Guidance

Movers

General

What's Going On With Constellation Brands Stock Today?

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $263.75, along with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is evident, with the current average reflecting a 0.96% increase from the previous average price target of $261.25.
<img src="https://www.benzinga.com/files/images/story/2024/1725379219_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Steris among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Steris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>Discovering Steris: A Closer Look</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Steris displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.12%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin excels beyond industry benchmarks, reaching 11.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Steris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.39.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Steris Stands With Analysts

Keybanc analyst Brett Fishbin maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $255 to $265.

Keybanc Maintains Overweight on Steris, Raises Price Target to $265

A new SEC filing reveals that CHRISTOPHER HOLLAND, Board Member at Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), made a notable insider purchase on August 12,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001757898/000162828024036792//Archives/edgar/data/1757898/000162828024036792/0001628280-24-036792-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that HOLLAND purchased 988 shares of Steris. The total transaction amounted to $236,803. 
Monitoring the market, Steris's shares down by 0.0% at $233.94 during Tuesday's morning.
<h3>Get to Know Steris Better</h3>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 8.12% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 44.74%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Steris's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.46.
</li>
</ul>
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 41.41 is lower than the industry average, implying a discounted valuation for Steris's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.44, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 18.19 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001757898">Check Out The Full List Of Steris's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Move: CHRISTOPHER HOLLAND Invests $236K In Steris Stock

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Steris

In the preceding three months, 4 analysts have released ratings for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $253.75, accompanied by a high estimate of $265.00 and a low estimate of $225.00. Marking an increase of 0.5%, the current average surpasses the previous average price target of $252.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1723064454_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Steris's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Steris's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Steris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Unraveling the Financial Story of Steris</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Steris displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.87%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.02%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Steris's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Steris: Insights From 4 Financial Analysts

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

Stephens &amp; Co. analyst Jacob Johnson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $260 price target.

Stephens & Co. Reiterates Overweight on Steris, Maintains $260 Price Target

STERIS plc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ste#NYSE">STE</a>) reported first-quarter fiscal 2025 adjusted earnings per share of $2.03, up 10.3% from the year-ago quarter&#39;s figure. The figure surpassed the Zacks Consensus Estimate by 2 cents.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges, among others.
The company&#39;s GAAP EPS was $1.41, up 7.6% from the year-ago level of $1.31. &nbsp;
<h3>Revenues in Detail</h3>
Revenues of $1.28 billion from continuing operations increased 8.5% year over year. The figure outpaced the Zacks Consensus Estimate by 1.5%.
Organic revenues at the constant exchange rate or CER rose 6% year over year.
<h3>Quarter in Detail</h3>
The company operates through three segments &mdash; Healthcare, Applied Sterilization Technologies (&quot;AST&quot;), and Life Sciences.
Revenues at&nbsp;Healthcare&nbsp;rose 10% year over year to $901.2 million (up 5% on a CER organic basis). While there was a 23% improvement in consumable revenues and a 14% increase in service revenues, these were partially offset by a 10% decline in capital equipment revenues.&nbsp; Our model expected Healthcare segment revenues to improve 6.9% in the fiscal first quarter.
Revenues at&nbsp;AST&nbsp;improved 7% to $249.8 million (up 8% on a CER organic basis). This performance reflected 7% growth in service revenues and a 24% increase in capital equipment revenues. Our model anticipated a 6.4% improvement in the segment&#39;s revenues in the reported quarter.
Revenues in the&nbsp;Life Sciences&nbsp;segment decreased 2% to $128.5 million (up 4% year over year on a CER organic basis). The decline in revenues was due to the divestiture of the CECS business. This performance reflected 13% growth in consumable revenues, offset by a 15% decline in capital equipment revenues and a 17% decline in service revenues. Our model projected a year-over-year improvement of 5.8% in the segment&#39;s revenues.
<h3>Margins</h3>
The gross profit in the reported quarter was $572.4 million, up 8.2% from the prior-year quarter. The gross margin expanded a marginal 4 basis points (bps) year over year to 44.7% due to an 8% rise in the cost of revenues.
STERIS witnessed a 9.5% year-over-year rise in selling, general and administrative expenses. The figure amounted to $335.6 million. Research and development expenses rose 3.6% to $25.6 million. Adjusted operating expenses of $361.2 million increased 9% year over year. The adjusted operating margin contracted 20 bps to 16.5%.
<h3>Financial Details</h3>
STERIS exited the first quarter of fiscal 2025 with cash and cash equivalents of $198.3 million compared with $207 million at the end of fiscal 2024.
<div class="chart_embed">
<h3>STERIS plc Price, Consensus and EPS Surprise</h3>
<img alt="STERIS plc Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/1e/1723034957.png" style="height:265px; width:590px" title="" />
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
</div>
Cumulative net cash flow from operating activities at the end of the fiscal first quarter was $303.7 million compared with $123.8 million in the year-ago period. Further, the company has a&nbsp;five-year&nbsp;annualized dividend growth rate of 8.44%.
<h3>Guidance</h3>
STERIS reiterated its fiscal 2025 projection.
The company expects revenues to increase 6.5-7.5%. Organic revenues are expected to be 5-7% at CER.
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $5.48 billion, implying 7.3% growth from fiscal 2024.
Adjusted EPS is expected to be in the range of $9.05-$9.25. The Zacks Consensus Estimate for the metric is pegged at $9.16.
<h3>Our Take</h3>
STERIS exited the first quarter of fiscal 2025 with better-than-expected results, wherein both adjusted earnings and revenues beat their respective consensus estimate. The ongoing momentum of the Healthcare segment is attributed to a solid procedure volume growth in the United States, along with favorable pricing.
The addition of the surgical instrumentation assets purchased from BD was a positive factor behind the strong growth of Healthcare operating income. Further, the AST segment reflected an improvement in capital equipment revenues and service revenues in the quarter under review. The expansion of the gross margin bodes well for the stock.
Meanwhile, performance in Life Sciences was dented due to the divestiture of the CECS business. The contraction of the operating margin is concerning.
<h3>Zacks Rank &amp; Key Picks</h3>
STERIS currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical, Abbott Laboratories, Inc.&nbsp;and Quest Diagnostics.
Intuitive Surgical reported a second-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has a long-term earnings growth rate of 16.1% for 2024 compared with the industry&#39;s 14.1%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.
Abbott, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2024 earnings of $1.14 per share, which surpassed the Zacks Consensus Estimate by 3.6%. Revenues of $10.38 billion topped the Zacks Consensus Estimate by 0.3%.
ABT has an earnings growth rate of 10.1% for 2025 compared with the S&amp;P 500&#39;s 9.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 2.34%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion outpaced the Zacks Consensus Estimate by 0.5%.
DGX has a historical five-year earnings growth rate of 7.4% compared with the industry&#39;s 4.2%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.
<a href="https://www.zacks.com/stock/news/2318207/steris-ste-q1-earnings-beat-estimates-operating-margin-falls?cid=CS-BENZ-FT-analyst_blog|earnings_article-2318207">To read this article on Zacks.com click here.</a>

Biotech

Earnings Beats

Large Cap

STERIS Q1 Earnings Beat Estimates, Operating Margin Falls

Fiscal 2025 Outlook Reiterated
For fiscal 2025, the Company continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Based on forward rates through March 31, 2025, currency is expected to be neutral to revenue in fiscal 2025. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. In April 2024, the Company completed a divestiture of its Controlled Environment Services business within the Life Sciences segment. Total annual revenue for this business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024. The fiscal 2025 outlook assumes an effective tax rate of approximately 23%. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.

STERIS Continues To Expect As Reported Revenue From Continuing Operations To Increase 6.5-7.5% In Fiscal 2025; Adjusted EPS To Be In The Range Of $9.05-$9.25 Vs $9.14 Est.

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.98 by 2.53 percent. This is a 1.5 percent increase over earnings of $2.00 per share from the same period last year.

Steris Q1 Adj $2.03 Beats $1.98 Estimate

STERIS&nbsp;plc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ste#NYSE">STE</a>) is expected to release first-quarter fiscal 2025 results on Aug 6.
<h3>Earnings Surprise History</h3>
STE has a strong earnings surprise history. It beat on earnings in three of the trailing four quarters and missed the same once, the average surprise being 2.21%.
In the last reported quarter, the company posted adjusted earnings per share of $2.41, in line with the Zacks Consensus Estimate.
<h3>Q1 Estimates</h3>
The Zacks Consensus Estimate for STERIS&#39; first-quarter fiscal 2025 revenues is pegged at $1.26 billion. This suggests a decrease of 1.7% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS of $2.03 indicates a year-over-year rise of 1.5%.
<h3>Estimate Revision Trend Ahead of Earnings</h3>
Estimates for STERIS&#39; fiscal first-quarter earnings have remained constant at $2.03 per share in the past 30 days.
Let&#39;s take a look at how things might have shaped up for the MedTech major before the announcement.
<h3>Factors at Play</h3>
Healthcare
In the fiscal fourth quarter, growth across capital equipment, consumables, and services was robust, favored by positive price and high productivity. This helped the company to offset the macro challenges affecting demand in the other segments. Considering a persistent favorable pricing scenario and stabilizing macroeconomic issues, the Healthcare arm of STERIS is expected to have continued its strong momentum in the fiscal first quarter of 2025 as well.
We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS&#39; focus on getting back to normal lead times must have helped it in meeting customer demand.&nbsp;
Additionally, in the previous earnings call, the company announced a targeted restructuring plan, which includes restructuring the Healthcare Surgical Capital business in Europe as well as other actions, including impairment of an internally developed high-capacity X-ray accelerator, product rationalizations and facility consolidations. This is likely to have benefited the Healthcare segment in the fiscal first quarter.
Our model projects the segment&#39;s revenues to improve 7.1% from the year-ago reported figure.
Applied Sterilization Technologies (AST)
Within the segment, the earlier-reported performances were adversely impacted by MedTech inventory destocking and the reduction of bioprocessing customer demand, both of which the company cites as short-term situations.
However, STE has been witnessing signs of recovery in the MedTech demand over the past couple of quarters, reflecting an improving procedure environment and the burndown of customer inventory in the United States. This impact might have lingered in the to-be-reported quarter as well.
During the fourth-quarter fiscal 2024 earnings call, the company projected no meaningful bioprocessing growth until the second half of fiscal 2025.
Per our model, the AST segment&#39;s revenues for the fiscal first quarter are likely to increase 6.4% year over year.
Life Sciences
STERIS, in its fiscal 2025 guidance, has mentioned a full-year impact from the divestiture of the Controlled Environmental Services business within the Life Sciences segment. This might have contributed to its revenues in the to-be-reported quarter. The Life Sciences business segment has ended fiscal 2024 in line with the long-term expectations. We expect this trend to have been maintained throughout the to-be-reported quarter.
<div class="chart_embed">
<h3>STERIS plc Price and EPS Surprise</h3>
<img alt="STERIS plc Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/60/1721735049.png" style="height:263px; width:544px" title="" />
STERIS plc price-eps-surprise | STERIS plc Quote
Our model projects the segment&#39;s revenues for the fiscal first quarter to increase 5.8% year over year.
</div>
Dental
On May 31, 2024, STERIS completed selling its Dental segment to Peak Rock Capital for $787.5 million. It will receive up to an additional $12.5 million in contingent payments, payable if the Dental business achieves certain revenue targets in fiscal year 2025. The proceeds will be primarily used to repay debt. For the fiscal first quarter, the company is expected to report one month of sales from the Dental business.
<h3>What Our Model Suggests</h3>
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive&nbsp;Earnings ESP, has a higher chance of beating estimates, which is not the case here.
Earnings ESP:&nbsp;STERIS has an Earnings ESP of 0.00%.
Zacks Rank:&nbsp;The company currently carries a Zacks Rank #2.
<h3>Stocks Worth a Look</h3>
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Hims &amp; Hers Health&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) has an Earnings ESP of +19.28% and a Zacks Rank #2 at present.
The company is set to release second-quarter 2024 results on Aug 5.
HIMS&#39; earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 79.17%. The Zacks Consensus Estimate for second-quarter EPS implies a surge of 266.7% from the year-ago quarter&#39;s reported figure.
TransMedics Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) has an Earnings ESP of +23.54% and a Zacks Rank #3 at present. The company is set to release second-quarter 2024 results on Aug 1.
TransMedics has an expected sales growth rate of 15.78% for 2024. TMDX beat on earnings in two of the trailing four quarters and missed in the other two, the average surprise being 9.93%.
Tenet Healthcare&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/thc#NYSE">THC</a>) has an Earnings ESP of +4.11% and a Zacks Rank #2 at present. The company is set to release second-quarter 2024 results on Jul 24.
THC has an expected long-term earnings growth rate of 12.5% compared to the industry&#39;s 11.9%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 56.50%.
<a href="https://www.zacks.com/stock/news/2306925/here-s-how-steris-ste-is-placed-ahead-of-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2306925">To read this article on Zacks.com click here.</a>

Health Care

Tech

Hims & Hers Health, Inc. Class A Common Stock

HIMS

TMDX

Here's How STERIS is Placed Ahead of Q1 Earnings

A large exercise of company stock options by JACQUELINE KOSECOFF, Director at Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) was disclosed in a new SEC filing on May 15, as part of an insider exercise.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001757898/000162828024023614//Archives/edgar/data/1757898/000162828024023614/0001628280-24-023614-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday revealed that KOSECOFF, Director at Steris in the Health Care sector, exercised stock options for 4,584 shares of STE stock. The exercise price of the options was $51.53 per share.
During Thursday's morning session, Steris shares down by 1.56%, currently priced at $231.78. Considering the current price, KOSECOFF's 4,584 shares have a total value of $826,288.
<h3>Get to Know Steris Better</h3>
Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
<h3>Understanding the Numbers: Steris's Finances</h3>
Revenue Growth: Steris's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 1.7%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 41.07%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Steris's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.01.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 42.43 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.55, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 30.37, Steris demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001757898">Check Out The Full List Of Steris's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Witnessing An Insider Decision, JACQUELINE KOSECOFF Exercises Options Valued At $826K At Steris

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Teva Pharmaceutical Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares surged 16.24% after the company reported mixed Q1 financial results and announced results from the efficacy portion of the Phase 3 SOLARIS trial of TEV-‘749 in adult patients with <a href="https://www.benzinga.com//node/38709408" target="_blank" rel="noreferrer noopener">schizophrenia compared to placebo</a>.</li>
<li>Toast, Inc. Class A&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) shares increased 14.71% on strong first-quarter&nbsp;2024 financial results, with revenue of&nbsp;$1.075 billion,&nbsp;<a href="https://www.benzinga.com//node/38684417" target="_blank" rel="noreferrer noopener">beating the&nbsp;estimates&nbsp;of&nbsp;$1.041 billion</a>. Several analysts raised the&nbsp;<a href="https://www.benzinga.com//node/38710825" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares were up 13.28% after the company reported <a href="https://www.benzinga.com//node/38715910" target="_blank" rel="noreferrer noopener">better-than-expected Q1 financial results.</a> Multiple analysts <a href="https://www.benzinga.com//node/38735571" target="_blank" rel="noreferrer noopener">lifted price targets on the stock</a>. </li>
<li>Vistra Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) shares rose 13.25% after it announced that it would join the S&amp;P 500, and a few analysts&nbsp;<a href="https://www.benzinga.com/quote/vst/analyst-ratings" target="_blank" rel="noreferrer noopener">raised the price target on the stock</a>.</li>
<li>International Flavors &amp; Fragrances, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) shares rose 11.22% after the company reported strong first-quarter results and expected FY24 revenue to trend towards the <a href="https://www.benzinga.com//node/38653308" target="_blank" rel="noreferrer noopener">higher end of its guidance range</a>. Several analysts increased <a href="https://www.benzinga.com/quote/iff/analyst-ratings" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>STERIS Plc (Ireland)&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) shares grew 10.72% after the company reported better-than-expected&nbsp;Q4&nbsp;financial results. The company announced a planned restructuring of its&nbsp;<a href="https://www.benzinga.com//node/38714045" target="_blank" rel="noreferrer noopener">healthcare surgical business in Europe</a>.</li>
<li>Constellation Energy Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares increased 8.56% after it reported mixed first-quarter FY24 results. Some analysts raised the&nbsp;<a href="https://www.benzinga.com/quote/ceg/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Emerson Electric Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) shares increased 7.99% after it reported better-than-expected&nbsp;Q2&nbsp;earnings and&nbsp;<a href="https://www.benzinga.com//node/38702517" target="_blank" rel="noreferrer noopener">raised its FY24&nbsp;guidance</a>. Many&nbsp;analysts made changes to&nbsp;<a href="https://www.benzinga.com//node/38728407" target="_blank" rel="noreferrer noopener">their price targets for the stock</a>.</li>
<li>Equinix, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) shares jumped 6.9% following&nbsp;mixed&nbsp;<a href="https://www.benzinga.com//node/38736613" target="_blank" rel="noreferrer noopener">first-quarter FY24&nbsp;earnings</a>.</li>
<li>International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) shares upped 5.68%  following a report suggesting Suzano offered <a href="https://www.benzinga.com//node/38681160" target="_blank" rel="noreferrer noopener">to acquire the company</a>.</li>
</ol>
See Also: <a href="https://www.benzinga.com/news/24/05/38779404/last-weeks-worst-performing-stocks-are-these-10-large-cap-stocks-in-your-portfolio-may-5-may-11-2024">Last Week's Worst-Performing Stocks: Are These Large-Cap Stocks In Your Portfolio? (May 5-May 11, 2024)</a>
Photo: Shutterstock

EQIX

TEVA

TOST

These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?

The healthcare industry's long-term growth is fueled by rising R&D initiatives and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid medical device stocks Alcon (ALC), Becton, Dickinson and Company (BDX), and STERIS (STE) for potential returns. Keep reading... The healthcare industry is well-positioned for significant expansion, driven by evolving demand amid the growing prevalence of chronic diseases and an aging population. Also, recent technological advances such as AI, big data analytics, and precision medicine have fueled the market prospects.
Amid this backdrop, investors could consider investing in quality healthcare stocks Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>), Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), and STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>) which are transforming towards patient care through innovation.
The <a href="https://www.deloitte.com/global/en/Industries/life-sciences-health-care/analysis/global-health-care-outlook.html">global healthcare industry is currently undergoing significant changes</a> owing to the challenge of quality, access, and affordability for the public worldwide. However, the adoption of intuitive technology like artificial intelligence (AI) also presents possible solutions to enhance processes and increase efficiency.
Recently, R&amp;D initiatives by healthcare organizations have also increased exponentially in segments like medical devices and pharmaceuticals. With this development, the global medical devices market is predicted to reach a staggering revenue of $508 billion in 2024. The industry is expected to <a href="https://www.statista.com/outlook/hmo/medical-technology/medical-devices/worldwide">grow at a CAGR of 5.7%</a>, resulting in a projected volume of $669.70 billion by 2029.
In global comparison, the U.S. medical devices market size is projected to grow from $188.68 billion in 2024 to <a href="https://www.fortunebusinessinsights.com/u-s-medical-devices-market-107009">$314.96 billion by 2032</a>, expanding at a CAGR of 6.6% driven by the increasing prevalence of chronic diseases, increasing healthcare expenses, and the existence of major manufacturers.
Also, rising investments by medical device companies for innovation to enhance their patent portfolios and <a href="https://www.medicaldevice-network.com/data-insights/artificial-intelligence-in-medical/?cf-view">leveraging AI</a> have opened lucrative deals and avenues. AI technologies improve healthcare operations and patient care, and the US is the leading country in its adoption, with the highest number of AI-related patents, jobs, and deals.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, beginning with the third choice.
Stock #3: Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>)
Headquartered in Geneva, Switzerland, ALC researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients globally. The company operates through the Surgical segment and the Vision Care segment.
On June 24, ALC's UNITY&#xAE; Vitreoretinal Cataract System (VCS) and UNITY&#xAE; Cataract System (CS) received the FDA 510(k) clearance. These innovations introduced significant workflow efficiencies over the company's current market-leading systems. Unity VCS and Unity CS are also the first innovations to be introduced from ALC's highly anticipated Unity portfolio.
Further, on March 12, ALC launched the Clareon&#xAE; Family of intraocular lenses in India. Clareon provides consistent visual outcomes and exceptional clarity that lasts as it was developed through ALC's most advanced IOL material.
ALC's net sales and other revenues for the second quarter that ended June 30, 2024, increased 3.1% year-over-year to $2.50 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> grew marginally from the year-ago value to $1.37 billion. The company's net income and EPS totaled $223 million and $0.45, up 31.9% and 32.3% from the prior year's quarter, respectively.
The company has maintained its 2024 outlook from the prior announcement. Net sales of ALC are forecasted between $9.90 billion and $10.10 billion, while its core EPS is expected to be $3 to $3.10.
Street expects ALC's revenue and EPS for the third quarter (ending September 2024) to increase 6% and 11.5% year-over-year to $2.47 billion and $0.74, respectively. Also, the company has topped the consensus EPS estimate in three of the trailing four quarters.
Shares of ALC have surged 10% over the past six months and 15.6% over the past year to close the last trading session at $94.47.
ALC's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Stability. It also has a B grade for Growth. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ALC is ranked #41 out of 132 stocks.
<a href="https://stocknews.com/stock/ALC/">Click here</a> to access additional ratings of ALC for Momentum, Sentiment, Value, and Quality.
Stock #2: Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public internationally. It operates in three segments: BD Medical; BD Life Sciences; and BD Interventional.
On September 3, BDX completed the acquisition of Edwards Lifesciences' Critical Care product group, to be renamed BD Advanced Patient Monitoring. The acquisition enables various future innovation opportunities and expands BDX's portfolio of smart connected care solutions with leading monitoring technologies, like advanced AI-enabled clinical decision tools.
On July 25, BDX and Quest Diagnostics (DGX), a leader in diagnostic information services, entered a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics. This can help in selecting the best treatment for patients with cancer and other diseases.
During the third quarter that ended June 30, 2024, BDX's adjusted revenues increased 3.7% year-over-year to $5.06 billion. Its operating income grew 9.7% from the year-ago value to $602 million. The company's net income and EPS came in at $487 million and $1.68, reflecting growths of 19.7% and 23.5% year-over-year, respectively.
As per the company's fiscal 2024 guidance, BDX expects adjusted revenue of $20.10 billion to $20.20 billion. It expects adjusted EPS between $13.05 and $13.15, at a projected growth of 6.9% to 7.7%.
Analysts expect the company's EPS for the fourth quarter (ending September 2024) to increase 10.1% year-over-year to $3.77, while its revenue is expected to grow 5.1% year-over-year to $5.34 billion. Moreover, BDX surpassed the consensus EPS estimates in three of the trailing four quarters.
BDX's shares have gained marginally over the past six months to close the last trading session at $236.34.
BDX's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Sentiment, Stability, and Growth. Within the Medical – Devices &amp; Equipment industry, BDX is ranked #27 out of 132 stocks.
In addition to the POWR Ratings we've stated above, we also have BDX ratings for Quality, Momentum, and Value. Get all BDX ratings <a href="https://stocknews.com/stock/BDX/">here</a>.
Stock #1: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE offers infection prevention products and services worldwide. The company operates through three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences.
On July 31, STE announced to distribute a quarterly interim dividend of $0.57 per share representing a $0.05 increase in the dividend. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024.
STE pays an annual dividend of $2.28, which translates to a yield of 0.94% at the current share price. Its four-year average dividend yield is 0.86%. Moreover, the company's dividend payouts have increased at a CAGR of 9.3% over the past three years. STERIS has raised its dividends for 13 consecutive years.
For the fiscal 2025 first quarter that ended June 30, 2024, STE's revenues increased 8.1% year-over-year to $1.28 billion. Its adjusted gross profit rose 8.8% from the year-ago value to $576.61 million. Adjusted net income attributable to shareholders and adjusted EPS came in at $212.64 million and $2.14, up 7.3% and 7% year-over-year, respectively.
In addition, the company's cash and cash equivalents and total assets stood at $198.33 million and $10.11 billion as of June 30, 2024.
For the fiscal year 2025, STE expects adjusted net income from continuing operations per share between $9.05 and $9.25. And its free cash flow is anticipated to be $700 million.
Street expects STE's revenue for the fourth quarter (ending March 2025) to increase marginally year-over-year to $1.50 billion. The company's EPS for the same quarter is expected to grow 2.7% year-over-year to $2.65. Also, the company surpassed the consensus revenue and EPS estimates in all of the trailing four quarters.
STE's stock has increased 3.1% over the past six months and 7.5% over the past year to close the last trading session at $239.84.
STE's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
STE has a B grade for Sentiment, Stability, and Growth. It is ranked #13 out of 132 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have STE ratings for Momentum, Value, and Quality. Get all STE ratings <a href="https://stocknews.com/stock/STE/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
BDX shares were trading at $233.94 per share on Thursday afternoon, down $2.40 (-1.02%). Year-to-date, BDX has declined -3.29%, versus a 16.29% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/bdx-alc-ste-3-healthcare-innovators-transforming-patient-care/>3 Healthcare Innovators Transforming Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Innovators Transforming Patient Care

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient needs. Read more… As innovation continues to shape nearly every industry, the medical sector is no exception. Now, you might wonder how the technology can influence the medical industry. The MedTech sector is innovating across various areas, including medical devices, diagnostics, digital health platforms, and robotic surgery.
These technological breakthroughs are creating unique opportunities for investors to invest in fundamentally sound companies like Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), which are innovating and advancing life-saving devices.
Over the past few years, the MedTech sector has experienced explosive growth, reshaping the healthcare industry in ways we never imagined, and it's showing no signs of slowing down. From $456.9 billion in 2020, the MedTech market is expected to soar to <a href="https://www.alpha-sense.com/blog/trends/medtech-trends-outlook/">$800 billion by 2030</a>. It's not just the numbers that are growing; healthcare companies are increasingly merging with MedTech firms to enhance their capabilities and gain a competitive edge.
Moreover, AI has been a game-changer in MedTech, driving breakthroughs in predictive diagnostics, remote monitoring, and precision medicine. With these advancements, the global market for medical devices is forecasted to <a href="https://www.globaldata.com/media/medical-devices/ai-to-drive-medical-devices-industry-to-1-2-billion-in-2027-forecasts-globaldata/">hit $1.2 billion</a> by 2027, exhibiting a CAGR of 29.1%.
Several factors fuel the growth of MedTech stocks, including an aging global population, the rising prevalence of chronic diseases, and a strong push toward digital transformation. As demand for more effective, efficient, and accessible healthcare solutions increases, MedTech companies are well-positioned to capitalize on these trends, making them a compelling investment opportunity for investors.
Considering these conducive trends, let's examine the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry stocks in detail, beginning with the third choice:
Stock #3: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, MDT provides healthcare technology solutions. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four segments: Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit.
On August 15, the company's board of directors approved a second-quarter dividend of $0.70 per share for fiscal year 2025, consistent with the company's previous dividend increase announced in May. The dividend will be paid on October 11, 2024, to shareholders of record as of September 27, 2024.
As a member of the S&amp;P 500 Dividend Aristocrats, MDT has raised its annual dividend for 47 consecutive years. It pays an annual dividend of $2.80 per share, which translates to a yield of 3.13% on the prevailing share price. Also, its four-year average dividend yield is 2.75%.
On August 7, MDT announced that the U.S. Food and Drug Administration (FDA) approved its Simplera&#x2122; continuous glucose monitor (CGM). It is the company's first disposable, all-in-one CGM, which is half the size of previous models and easier to use.
Additionally, the company revealed a global partnership with Abbott to create an integrated CGM based on Abbott's latest technology, exclusively compatible with MDT's smart insulin device. The company will sell this system exclusively and expects the partnership to boost its Diabetes revenue while maintaining its gross margin.
MDT's net sales for the first quarter (ended July 26, 2024) increased 2.8% year-over-year to $7.92 billion. Its non-GAAP operating profit grew 2.3% from the prior year's quarter to $1.95 billion. The company's attributable net income rose 31.7% from the year-ago value to $1.04 billion, while its non-GAAP <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> stood at $1.23, up 2.5% year-over-year.
The company has updated its fiscal year 2025 outlook, increasing its revenue growth projection to a range of 4.5% to 5%, up from the previous estimate of 4% to 5%. Additionally, it has adjusted its non-GAAP EPS guidance to a new range of $5.42 to $5.50, slightly higher than the prior forecast of $5.40 to $5.50. This revised guidance suggests a 4% to 6% growth in non-GAAP EPS.
The consensus revenue estimate of $8.41 billion for the fiscal third quarter (ending January 2025) represents a 3.9% increase year-over-year. The consensus EPS estimate of $1.37 for the same quarter indicates a 5.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past nine months, the stock has surged 13.5%, closing the last trading session at $89.39.
MDT's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
MDT has a B grade for Stability. It is ranked #19 out of 132 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/MDT/">Click here</a> to see the additional ratings for MDT (Growth, Value, Momentum, Sentiment, and Quality).
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE is a provider of products and services that support patient care with an emphasis on infection prevention worldwide. It operates through three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. 
On July 31, buoyed by strong financial performance, the company increased its quarterly interim dividend by $0.05 to $0.57 per share, payable to its shareholders on September 20, 2024.
With 19 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 0.95% at the current share price. Its four-year average dividend yield is 0.86%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 9.3% over the past three years.
For the first quarter of 2024, which ended on June 30, STE's total revenues increased 8.1% year-over-year to $1.28 billion, while its gross profit stood at $572.43 million, up 8.2% year-over-year. Its net income attributable for the quarter amounted to $145.40 million or $1.46 per share, representing an increase of 17.7% and 16.8%, respectively, from the same period last year. Also, the company's net cash flow from operating activities grew 8% from the year-ago value to $303.74 million.
As per the updated guidance for the fiscal year 2025, STE forecasts revenue from continuing operations to increase 6.5% to 7.5% from 2024. The company also expects adjusted EPS from continuing operations between $9.05 and $9.25 and free cash flow to be approximately $700 million.
Analysts expect STE's revenue for the fiscal year ending March 2025 to grow marginally year-over-year to $5.50 billion, while its EPS for the same period is expected to increase 3.8% from the prior year to $9.16.
STE shares have surged 20.4% over the past nine months to close the last trading session at $239.05.
STE's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth, Stability, and Sentiment. Within the same industry, it is ranked #13 out of 132 stocks. <a href="https://stocknews.com/stock/STE/">Click here</a> to see STE's ratings for Value, Momentum, and Quality.
Stock #1: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products worldwide. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies, diversifying HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter. Its adjusted EBITDA increased 8.5% year-over-year to $338.50 million.
HOLX's non-GAAP net income came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with EPS anticipated to fall between $0.80 and $0.87. On a consolidated adjusted basis, its non-GAAP EPS is expected to range from $0.97 to $1.04.
Street expects HOLX's revenue for the fiscal fourth quarter (ending September 2024) to increase 3.4% year-over-year to $977.72 million. Its EPS for the same period is expected to register a 13.8% growth from the prior year, settling at $1.01. In addition, it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters, which is promising.
Shares of HOLX have gained 16.9% over the past nine months to close the last trading session at $80.99.
It's no surprise that HOLX has an overall rating of B, equating to a Buy in our POWR Ratings system. It has a B grade for Growth and Quality. Out of 132 stocks in the Medical - Devices &amp; Equipment industry, HOLX is ranked #10.
Beyond what is stated above, we've also rated HOLX for Value, Momentum, Stability, and Sentiment. Get all HOLX ratings <a href="https://stocknews.com/stock/HOLX/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
MDT shares were trading at $89.88 per share on Friday afternoon, up $0.49 (+0.55%). Year-to-date, MDT has gained 10.98%, versus a 14.67% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/mdt-ste-holx-3-medtech-stocks-revolutionizing-healthcare/>3 MedTech Stocks Revolutionizing Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Stocks Revolutionizing Healthcare

Dividend Champion, Contender, And Challenger Highlights: Week Of September 15

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report), Altim...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)

Piper Sandler analyst Jason Bednar upgraded the rating on Steris (STE – Research Report) to a Buy today, setting a price target of $260.00. Jason B...

Steris: Attractive Risk/Reward Profile and Strong Growth Potential Justify Buy Rating

Piper Sandler upgraded Steris (STE) to Overweight from Neutral with a price target of $260, up from $230. The upgrade is more a call that the negat...

Steris upgraded to Overweight from Neutral at Piper Sandler

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

Steris raised to overweight by Piper Sandler, valuation cited

JMP Securities analyst David Turkaly has reiterated their bullish stance on STE stock, giving a Buy rating yesterday. David Turkaly's rating is bas...

Steris's Strong Financial Performance and Strategic Focus Drive Positive Analyst Rating

ALLE

AMSF

APLO

AVGO

CATX

CBSH

CCBG

CGEM

CGON

CINF

CTVA

EVRG

EXPO

FITB

FRME

GAIN

GOLF

HAFC

HOLX

IDYA

IOVA

JANX

JJSF

KURA

LAND

LOGI

LRCX

MBWM

MOFG

MRUS

NRIX

NUVL

ODFL

OTEX

PRGO

RBCAA

SAMG

SBAC

SIRI

SLGN

SNDX

SWBI

TCBK

UNTY

UTMD

VICI

Press Releases

STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024

Dividends

STERIS Announces Dividend of $0.52 per share

STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year

PEAK ROCK CAPITAL AFFILIATE COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION OF HUFRIEDYGROUP

STERIS to Host a Conference Call for Fiscal 2025 First Quarter Financial Results on August 7, 2024

STERIS Raises Dividend to $0.57 per share

STERIS Announces Financial Results for Fiscal 2025 First Quarter

STERIS to Present at the Morgan Stanley Healthcare Conference

STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024

STERIS Declares Dividend of $0.57 per share

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Steris

Notizie

Ultime notizie per Steris (NYSE:STE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO